Printer Friendly

MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)

             MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT
                ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
    SAN DIEGO, June 18 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) and Mallinckrodt Medical Inc. (a unit of IMCERA Group (NYSE: IMA)) today announced that a New Drug Submission (NDS) for MBI's cardiac ultrasound contrast imaging agent, Albunex(R), has been filed with Canada's Health Protection Branch (HPB). Mallinckrodt Medical Inc., located in St. Louis, has exclusive marketing and distribution rights for Albunex in North and South America.
    The NDS, filed earlier this month with the HPB in Ottawa, Ontario is for the use of Albunex with 2-D echocardiography (ultrasound of the heart).  A similar submission has been made to the U.S. Food and Drug Administration (FDA) and is currently scheduled to be reviewed by its Radiology Device Advisory Panel on July 14, 1992.
    Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging and computed tomography.  Its flagship product, Albunex, is currently, in the final stages of the FDA's pre-market approval process.  MBI's marketing and distribution partners for Albunex include Mallinckrodt Medical Inc. (a unit of IMCERA Group), Shionogi & Co. Ltd. and Hafslund Nycomed AS.
    -0-                     6/18/92
    /CONTACT:  Beth Field Wallace (investors) of Molecular Biosystems, 619-452-0681/
    (MB IMA) CO:  Molecular Biosystems Inc.; Mallinckrodt Medical Inc.;
     IMCERA Group ST:  California; Missouri IN:  MTC SU: JL-EH -- SD004 -- 1424 06/18/92 10:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 18, 1992
Words:245
Previous Article:PETER STARRETT NAMED PRESIDENT, WORLDWIDE RETAIL, WARNER BROS. CONSUMER PRODUCTS
Next Article:MICHIGAN BOATING INDUSTRIES ASSOCIATION TO PRODUCE NOVI BOATING EXPO
Topics:


Related Articles
IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY
IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
IMCERA REPORTS SIGNIFICANT INCREASE IN FISCAL 1993 FIRST QUARTER EARNINGS FROM CONTINUING OPERATIONS
MOLECULAR BIOSYSTEMS RECEIVES FDA LETTER REGARDING ALBUNEX(R) PMA AMENDMENT
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
MBI DELIVERS UPDATE ON ALBUNEX
Phase 3 Clinical Findings Submitted on use of ALBUNEX(R) for Fallopian Tube Patency
Molecular Biosystems, Mallinckrodt File For PMA for Next Generation Ultrasound Imaging Agent, FS069
Molecular Biosystems, Mallinckrodt Expand Partnership for Marketing of FS069
Brand Name Chosen for Proposed Ultrasound Imaging Agent FS069

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters